Method for reducing chloride secretion by intestinal epithelial cells in situ: use of triaryl methane compounds

A veterinary preparation comprising:

• an aromatic compound in an amount effective to inhibit scours in a subject, the aromatic compound having the general formula:
• 107
• or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• n is 0, 1, 2, 3 or 4;
• p is 0 or 1;
• X is absent, (C1-C3) alkyl, (C1-C3) alkenyl, (C1-C3) alkynyl, SCH2, OCH2,or NOCH2;
• Y is C, N, P, Si or Ge;
• R′ is absent, -halo, —R, —OR, —SR, —NR2, —ONR2, —NO2, —CN, —C(O)R, —C(S)R, —C(O)OR, —C(S)OR, —C(O)SR, —C(S)SR, —C(O)NR2, —C(S)NR2, —C(O)NR(OR), —C(S)NR(OR), —C(O)NR(SR), C(S)NR(SR), —CH(CN)2, —CH[C(O)R]2, —CH[C(S)R]2, —CH[C(O)OR]2, —CH[C(S)OR]2, —CH[C(O)SR]2, —CH[C(S)SR]2, aryl, or heteroaryl;
• Ar1 is aryl, substituted aryl, heteroaryl, (C5-C8) cycloalkyl or (C5-C8) heterocycloalkyl;
• Ar2 is aryl or substituted aryl;
• Ar3 is aryl, substituted aryl, biaryl, biphenyl, bibenzyl, or heteroaryl other than imidazole, nitroimidazole and triazole;
• each R is independently selected from the group consisting of —H, (C1-C6) alkyl, substituted (C1-C6) alkyl, (C1-C6) alkenyl, substituted (C1-C6) alkenyl (C1-C6) alkynyl, substituted (C1-C6) alkynyl, and (C1-C6) alkoxy;
• the aryl substituents are each independently selected from the group consisting of -halo, trihalomethyl, —R, —R1, —OR1, —SR1, NR12, —NO2, —CN, —C(O)R1, —C(S)R1, —C(O)OR1, —C(S)OR1, —C(O)SR1 and —C(S)SR1;
• the alkyl, alkenyl and alkynyl substituents are each independently selected from the group consisting of -halo, —R1, —OR1, —SR1, N(R1)2, —NO2, —CN, —C(O)R1, —C(S)R1, —C(O)OR1, —C(S)OR1, —C(O)SR1, —C(S)SR1, aryl, γ-butyrolactonyl, pyrrolidinyl and succinic anhydridyl;
• and each R1 is independently selected from the group consisting of —H, (C1-C6) alkyl, (C1-C6) alkenyl and (C1-C6) alkynyl.
• ;
• and,
• an anti-scours agent

A pharmaceutical preparation, comprising:

• an aromatic compound in an amount effective to inhibit diarrhea, the aromatic compound having the general formula:
• 109
• or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• n is 0, 1, 2, 3 or 4;
• p is 0 or 1;
• X is absent, (C1-C3) alkyl, (C1-C3) alkenyl, (C1-C3) alkynyl, SCH2, OCH2,or NOCH2;
• Y is C, N, P, Si or Ge;
• R′ is absent, -halo, —R, —OR, —SR, —NR2, —ONR2, —NO2, —CN, —C(O)R, —C(S)R, —C(O)OR, —C(S)OR, —C(O)SR, —C(S)SR, —C(O)NR2, —C(S)NR2, —C(O)NR(OR), —C(S)NR(OR), —C(O)NR(SR), C(S)NR(SR), —CH(CN)2, —CH[C(O)R]2, —CH[C(S)R]2, —CH[C(O)OR]2, —CH[C(S)OR]2, —CH[C(O)SR]2, —CH[C(S)SR]2, aryl, or heteroaryl;
• Ar1 is aryl, substituted aryl, heteroaryl, (C5-C8) cycloalkyl or (C5-C8) heterocycloalkyl;
• Ar2 is aryl or substituted aryl;
• Ar3 is aryl, substituted aryl, biaryl, biphenyl, bibenzyl, or heteroaryl other than imidazole, nitroimidazole and triazole;
• each R is independently selected from the group consisting of —H, (C1-C6) alkyl, substituted (C1-C6) alkyl, (C1-C6) alkenyl, substituted (C1-C6) alkenyl (C1-C6) alkynyl, substituted (C1-C6) alkynyl, and (C1-C6) alkoxy;
• the aryl substituents are each independently selected from the group consisting of -halo, trihalomethyl, —R, —R1, —OR1, —SR1, NR12, —NO2, —CN, —C(O)R1, —C(S)R1, —C(O)OR1, —C(S)OR1, —C(O)SR1 and —C(S)SR1;
• the alkyl, alkenyl and alkynyl substituents are each independently selected from the group consisting of -halo, —R1, —OR1, —SR1, N(R1)2, —NO2, —CN, —C(O)R1, —C(S)R1, —C(O)OR1, —C(S)OR1, —C(O)SR1, —C(S)SR1, aryl, γ-butyrolactonyl, pyrrolidinyl and succinic anhydridyl;
• and each R1 is independently selected from the group consisting of —H, (C1-C6) alkyl, (C1-C6) alkenyl and (C1-C6) alkynyl;
• and,
• an anti-diarrheal agent.

A method for treating scours, the method comprising the step of:

• administering to a subject in need of such treatment, an aromatic compound in an amount effective to inhibit scours, wherein the aromatic compound has the general formula:
• 111
• or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• n is 0, 1, 2, 3 or 4;
• p is 0 or 1;
• X is absent, (C1-C3) alkyl, (C1-C3) alkenyl, (C1-C3) alkynyl, SCH2, OCH2,or NOCH2;
• Y is C, N, P, Si or Ge;
• R′ is absent, -halo, —R, —OR, —SR, —NR2, —ONR2, —NO2, —CN, —C(O)R, —C(S)R, —C(O)OR, —C(S)OR, —C(O)SR, —C(S)SR, —C(O)NR2, —C(S)NR2, —C(O)NR(OR), —C(S)NR(OR), —C(O)NR(SR), C(S)NR(SR), —CH(CN)2, —CH[C(O)R]2, —CH[C(S)R]2, —CH[C(O)OR]2, —CH[C(S)OR]2, —CH[C(O)SR]2, —CH[C(S)SR]2, aryl, or heteroaryl;
• Ar1 is aryl, substituted aryl, heteroaryl, (C5-C8) cycloalkyl or (C5-C8) heterocycloalkyl;
• Ar2 is aryl or substituted aryl;
• Ar3 is aryl, substituted aryl, biaryl, biphenyl, bibenzyl, or heteroaryl other than imidazole, nitroimidazole and triazole;
• each R is independently selected from the group consisting of —H, (C1-C6) alkyl, substituted (C1-C6) alkyl, (C1-C6) alkenyl, substituted (C1-C6) alkenyl (C1-C6) alkynyl, substituted (C1-C6) alkynyl, and (C1-C6) alkoxy;
• the aryl substituents are each independently selected from the group consisting of -halo, trihalomethyl, —R, —R1, —OR1, —SR1, NR12, —NO2, —CN, —C(O)R1, —C(S)R1, —C(O)OR1, —C(S)OR1, —C(O)SR1 and —C(S)SR1;
• the alkyl, alkenyl and alkynyl substituents are each independently selected from the group consisting of -halo, —R1, —OR1, —SR1, N(R1)2, —NO2, —CN, —C(O)R1, —C(S)R1, —C(O)OR1, —C(S)OR1, —C(O)SR1, —C(S)SR1, aryl, γ-butyrolactonyl, pyrrolidinyl and succinic anhydridyl;
• and each R1 is independently selected from the group consisting of —H, (C1-C6) alkyl, (C1-C6) alkenyl and (C1-C6) alkynyl.